SkinBioTherapeutics
plc
("SkinBioTherapeutics" or "the Company")
Senior Croda Vice President
joins SkinBioTherapeutics as
Cosmetic Science / Customer Alliances Advisor to the
Board
Recognised as one of Croda's
senior researchers in cosmetic ingredients
29
July 2024 - SkinBioTherapeutics plc
(AIM: SBTX), a life
science company focused on skin health, announces the appointment
of Dr Surinder 'Dass' Chahal as Cosmetic
Science / Customer Alliances Advisor to the Board.
Dr Chahal has been closely involved
with SkinBioTherapeutics since the signing of the commercial and
manufacturing agreement in November 2019 between
SkinBioTherapeutics and Croda's Consumer Care division, Sederma,
which is the specialist in bioactive ingredients for the cosmetics
industry. His role will be the interface with Croda as the
partnership moves into commercialisation. He will also advise on
cosmetic science and assist the Company in strategic alliances with
other multinationals.
Dr Chahal's career at Croda
International PLC (Croda or the Group), one of the world's leading
speciality ingredients manufacturers, has spanned over 37 years. He
joined Croda in 1987, initially leading cosmetic protein innovation
at the Group, then moved onto a variety of roles including
Enterprise Technologies which involved open innovation, technology
investment, and he went on to establish Croda's biotechnology
research group. In 2014 he was appointed to Croda's Global Personal
Care Board as Vice President Research & Development, then was
appointed as VP Long-Term Innovation covering strategic research
and technology acquisition.
He rose to become part of the
Long-Term Innovation group as VP Customer Alliances (Technology
Development) working as part of the CSO's senior technology team
across all Croda businesses. He is recognised as one of Croda's
senior researchers in the field of cosmetic ingredients.
Dr Chahal has a B.Sc. (Hons)
Chemistry and a PhD in Chemistry and Chemical technology from the
University of Bradford.
Martin Hunt, Chairman of
SkinBioTherapeutics, said:
"We are absolutely delighted to have
Dass act as a senior advisor to the Board. He has had a
distinguished career at Croda across a variety of roles, each of
which enables him to provide valuable insight and advice to us as
we develop and commercialise our various business pillars. We have
got to know him through our partnership with Croda and he has been
instrumental in building the strong relationship that we have with
both the Croda and Sederma teams. We are very much looking forward
to having him as part of the advisory team."
Dr Chahal added:
"I have been a great supporter of
the team at SkinBioTherapeutics ever since I first saw the
Skinbiotix technology and realised its potential across multiple
segments of skin healthcare. The Company may be relatively small
compared to Croda, but it has achieved a tremendous amount in a
short period. As I complete my career at Croda, I am delighted to
still be involved with the SkinBioTherapeutics team and its
technology."
-Ends-
The information communicated in this announcement contains
inside information for the purposes of Article 7 of the Market
Abuse Regulation (EU) No. 596/2014.
For
more information please contact:
|
SkinBioTherapeutics plc
Stuart J. Ashman, CEO
Manprit Randhawa, CFO
|
+44 (0) 191 495
7325
|
|
Cavendish Capital Markets Limited
(Nominated Adviser & Broker)
Giles Balleny, Dan Hodkinson
(Corporate Finance)
Charlie Combe (Broking)
Dale Bellis, Tamar Cranford-Smith
(Sales)
|
+44 (0) 20 7220
0500
|
|
Vigo
Consulting (financial press)
Rozi Morris
|
+44 (0) 20 7390
0230
SkinBio@vigoconsulting.com
|
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life
science company focused on skin health. The Company's proprietary
platform technology, SkinBiotix®, is based upon discoveries made by
the translational dermatology team at the University of
Manchester.
The Company is targeting a number of
skin healthcare sectors, the most advanced of which are cosmetic
skincare and food supplements to modulate the immune system by
harnessing the gut-skin axis. In each area SkinBioTherapeutics
plans to exemplify its technology through human studies. The
Company's first product, AxisBiotix-Ps™, a food supplement to
address the symptoms of mild to moderate psoriasis.
The Company listed on AIM in April
2017 and is based in Newcastle, UK. For more information,
visit: www.skinbiotherapeutics.com.